Chapter 16  ·  Module 1  ·  Introduction to Medical Pharmacology

Dopamine Pathways and the Neurobiological Basis of Psychosis

Visual summary of the four dopamine circuits, receptor subtypes, and symptom dimensions of schizophrenia

The Four Dopaminergic Pathways

Pathway 1 — Therapeutic   Mesolimbic
OriginVentral tegmental area
TargetNucleus accumbens, limbic structures
FunctionReward, motivational salience
In psychosisOveractive → positive symptoms
BlockadeReduces hallucinations and delusions
Pathway 2 — Problem   Mesocortical
OriginVentral tegmental area
TargetPrefrontal cortex
FunctionWorking memory, executive function
In psychosisUnderactive → negative symptoms, cognitive deficits
BlockadeWorsens already-deficient pathway
Pathway 3 — Side Effects   Nigrostriatal
OriginSubstantia nigra pars compacta
TargetStriatum (caudate and putamen)
FunctionMotor control (lost in Parkinson disease)
In psychosisNormal — not part of disease
BlockadeExtrapyramidal symptoms, tardive dyskinesia
Pathway 4 — Hormonal   Tuberoinfundibular
OriginHypothalamic arcuate nucleus
TargetAnterior pituitary
FunctionDopamine tonically inhibits prolactin release
In psychosisNormal — not part of disease
BlockadeHyperprolactinemia → galactorrhea, amenorrhea

Receptor Binding and Clinical Consequences

Receptor Blockade Consequence High-Burden Agents Low-Burden Agents Clinical Note
D2 (dopamine) Antipsychotic effect; extrapyramidal symptoms; hyperprolactinemia All antipsychotics — Primary target; occupancy 65–80% needed for effect
5-HT2A (serotonin) Reduced extrapyramidal symptoms; partial mesocortical dopamine restoration Clozapine, olanzapine, quetiapine Haloperidol, fluphenazine Defines "atypicality" — the higher the ratio vs. D2, the lower the motor side effect burden
H1 (histamine) Sedation; weight gain (appetite stimulation) Clozapine, olanzapine, quetiapine Aripiprazole, ziprasidone, lurasidone Major driver of antipsychotic-induced metabolic effects
M1 (muscarinic) Dry mouth, urinary retention, constipation, cognitive impairment Clozapine, thioridazine, chlorpromazine Haloperidol, risperidone, aripiprazole Central M1 blockade worsens cognition — problem in schizophrenia
Alpha-1 (adrenergic) Orthostatic hypotension, reflex tachycardia, dizziness Clozapine, chlorpromazine, iloperidone Haloperidol, aripiprazole Requires gradual dose titration; especially hazardous in elderly patients

Three Symptom Dimensions of Schizophrenia

Positive Symptoms

  • Hallucinations (auditory most common)
  • Delusions (paranoid most common)
  • Disorganized thinking and behavior

Substrate: mesolimbic dopamine excess
Response: respond well to antipsychotics

Negative Symptoms

  • Blunted affect (reduced expressivity)
  • Alogia (reduced speech)
  • Avolition (reduced motivation)
  • Anhedonia, asociality

Substrate: mesocortical dopamine deficiency
Response: respond poorly; may worsen on first-generation antipsychotics

Cognitive Symptoms

  • Working memory impairment
  • Attention deficits
  • Reduced processing speed
  • Executive function deficits

Substrate: prefrontal dopamine D1 hypostimulation
Response: no approved pharmacological treatment

Key Principle: All antipsychotics block dopamine D2 receptors in all four pathways simultaneously. The therapeutic effect (mesolimbic) and the adverse effects (nigrostriatal, tuberoinfundibular, mesocortical) are all consequences of the same mechanism operating in different anatomical locations.

Second-generation advantage: Adding serotonin 5-HT2A blockade partially restores dopamine tone in the nigrostriatal and mesocortical pathways, reducing motor side effects — but at the cost of increased metabolic adverse effects (H1 and serotonin 5-HT2C blockade driving weight gain and glucose dysregulation).